VU 0155041 sodium salt
Potent, positive allosteric modulator/allosteric agonist at mGlu4 receptors (EC50 = 798 and 693 nM at human and rat mGlu4 receptors respectively). Active in in vivo models of Parkinson's disease following i.c.v. administration. Sodium salt of VU 0155041 (Cat. No. 3248).
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 338.16. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.96 mL||14.79 mL||29.57 mL|
|5 mM||0.59 mL||2.96 mL||5.91 mL|
|10 mM||0.3 mL||1.48 mL||2.96 mL|
|50 mM||0.06 mL||0.3 mL||0.59 mL|
References are publications that support the products' biological activity.
Niswender et al (2008) Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Mol.Pharmacol. 74 1345 PMID: 18664603
If you know of a relevant reference for VU 0155041 sodium salt, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: VU 0155041 sodium salt, supplier, Potent, positive, allosteric, mGlu4, mGluR4, agonists, Sodium, salt, mGlur, Group, III, Receptors, Glutamate, Metabotropic, VU0155041, sodium, Glutamate, (Metabotropic), Group, III, Receptors, Glutamate, (Metabotropic), Group, III, Receptors, Tocris Bioscience
Citations for VU 0155041 sodium salt
Citations are publications that use Tocris products.
Currently there are no citations for VU 0155041 sodium salt. Do you know of a great paper that uses VU 0155041 sodium salt from Tocris? If so please let us know.
VU 0155041 sodium salt Reviews
Average Rating:(Based on 0 Reviews)
Literature in this Area
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.